Opti Medical Systems

What Opti Medical Systems does

OPTI Medical Systems, Inc. is a Georgia-based, wholly-owned subsidiary of IDEXX Laboratories, Inc. (NASDAQ: IDXX) that designs, manufactures, and globally distributes point-of-care blood gas and electrolyte analyzers, plus a growing line of molecular diagnostic test kits. The company's flagship products — the OPTI CCA, OPTI CCA-TS, and OPTI CCA-TS2 analyzers — rely on a patented optical fluorescence sensor architecture (optodes) that eliminates electrode maintenance and uses single-use disposable cassettes for calibration, measurement, and sealed waste containment. During the COVID-19 pandemic the company leveraged IDEXX's PCR manufacturing expertise in Montpellier, France, to introduce the OPTI SARS-CoV-2 RT-PCR test kit (FDA EUA May 2020, CE Mark June 2020), followed by the OPTI Rapid Lysis Buffer for extraction-free workflows (June 2021) and a multiplex SARS-CoV-2/Influenza A/B RT-PCR test (April 2022).

The business operates a hybrid razor/razorblade model: hardware sales of analyzers are paired with a recurring consumables stream from a menu of single-use cassettes (B-Type, E-Ca, E-Cl, E-GLU, B-LAC, B60, E-Lyte CCA) and complementary molecular test kits. Revenue is generated through direct sales to small- and medium-sized hospitals and CLIA-certified high-complexity laboratories, supported by a worldwide authorized distributor network and IDEXX's own order portal reaching more than 175 countries. An installed base of 10,000+ instruments globally anchors the consumables flywheel, with ancillary revenue from the ComfortSampler arterial blood collection kit and the no-charge Online Quality Assurance Program (QAP), which drives customer stickiness. The company is privately held; revenue is not separately reported by IDEXX.

OPTI Medical traces its lineage to AVL Medical Instruments (1967), entered the U.S. market in 1995, passed through Roche Diagnostics and Osmetech plc, and was acquired by IDEXX in January 2007 for $44.9 million as part of the larger Critical Care Division transaction. The company maintains its own Roswell-based leadership team — including General Manager Bryan Briggs and Director of Regulatory/QA/QC Theron Gober — and benefits from IDEXX's regulatory affairs, manufacturing scale, and global distribution muscle. Headcount is reported in the 101–250 range, consistent with a focused mid-size diagnostics subsidiary rather than a standalone enterprise.

Name

Opti Medical Systems

Legal name

OPTI Medical Systems, Inc.

Website

https://optimedical.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

OPTI Medical Systems, a subsidiary of IDEXX Laboratories, designs and manufactures point-of-care blood gas and electrolyte analyzers using patented optical fluorescence (optode) technology and single-use cassettes, plus molecular diagnostic PCR kits, serving hospitals, CLIA-certified laboratories, and public health agencies across 175+ countries with an installed base of 10,000+ instruments.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Analytical Laboratory Instrument Manufacturing (334516)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Anesthesia & Respiratory Gas Delivery Equipment (Breathing Circuits, Vaporizers, Gas Mixers) (HLAHAGAK)

Keywords

• Blood gas analyzers
• In vitro diagnostics
• Medical devices
• Point-of-care testing
• Diagnostic instruments

Headquarters

HQ city

Roswell

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Blood Gas and Electrolyte Analyzers: Sale of portable OPTI blood gas analyzers including OPTI CCA, OPTI CCA-TS, and OPTI CCA-TS2. Analyzers use single-use disposable cassettes for measurements.
2. Single-Use Diagnostic Cassettes: Consumable revenue from sale of single-use disposable cassettes in various configurations (B-Type, E-Ca Type, E-Cl Type, E-GLU Type, B-LAC Type, B60 Type, E-Lyte CCA Type) for different test parameters.
3. COVID-19 PCR Test Kits: Sale of OPTI SARS-CoV-2 RT-PCR test kits for detection of COVID-19, including the OPTI SARS-CoV-2/Influenza A/B combination test.
4. Quality Assurance Programs: Online Quality Assurance Program (QAP) provided at no additional charge to OPTI analyzer users, adding customer value and loyalty.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

Opti Medical Systems manufactures portable blood gas analyzers and COVID-19 PCR test kits, applying proprietary optical fluorescence (optodes) technology. Its products are sold to hospitals, emergency departments, and critical care settings for point-of-care in vitro diagnostic use.

Product overview

OPTI Medical Systems specializes in point-of-care and laboratory diagnostic solutions using optical fluorescence technology. The product portfolio centers on the OPTI CCA-TS2 as the flagship next-generation blood gas and electrolyte analyzer, supported by the earlier OPTI CCA and OPTI CCA-TS models. These analyzers use optical fluorescence sensors (optodes) eliminating electrode maintenance. The analyzer system is complemented by single-use disposable cassette configurations (B-Type, E-Ca, E-Cl, E-GLU, B-LAC, B60, E-Lyte CCA) for different test panels, and the ComfortSampler Arterial Blood Gas Collection Kit for sample collection. The Online Quality Assurance Program (QAP) provides web-based QC data management with peer comparison. During the COVID-19 pandemic, OPTI expanded into molecular diagnostics with the OPTI SARS-CoV-2 RT-PCR Test Kit, OPTI SARS-CoV-2/Influenza A/B RT-PCR Test, OPTI Rapid Lysis Buffer for extraction-free testing, and OPTI DNA/RNA Magnetic Bead Kit. All diagnostic products leverage IDEXX's expertise in PCR test development and manufacturing, with facilities in Montpellier, France. The company operates as a subsidiary of IDEXX Laboratories with over 10,000 instruments in use worldwide.

Differentiator

Problem solved

Functional benefit

Products and services

• Portable Blood Gas Analyzers Portable blood gas analyzers manufactured by Opti Medical Systems using proprietary optical fluorescence (optodes) technology, sold to hospitals, emergency departments, and critical care settings for point-of-care in vitro diagnostic use.
• COVID-19 PCR Test Kits COVID-19 PCR test kits produced by Opti Medical Systems for diagnostic use in clinical and laboratory settings.

Quantifiable outcome

• Over 10,000 instruments in use worldwide
• +3 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature6 records

Partnerships

One partnership is on record.

• Institut Pasteur of FrancecoreStrategic or Co-development PartnerInstitut Pasteur of France validated the OPTI SARS-CoV-2 RT-PCR test kit prior to FDA Emergency Use Authorization. This validation was a critical step in regulatory approval for COVID-19 testing.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cepheid (Danaher): GeneXpert molecular PCR system widely deployed for infectious disease testing including SARS-CoV-2 and multiplex respiratory panels. Directly comparable to OPTI's RT-PCR test kits as a CLIA-lab molecular diagnostics platform.
• Radiometer (Danaher): Direct competitor in POC and central-lab blood gas analyzers (ABL90, ABL800), with the broadest installed base in large hospital labs worldwide. Closest direct peer to OPTI's CCA-TS2 product line.
• Werfen (Instrumentation Laboratory): Manufactures the GEM Premier 5000 blood gas and electrolyte analyzer family used in hospital POC settings. Directly comparable point-of-care platform with similar menu and consumable cassette economics.
• Abbott (i-STAT): i-STAT 1 and i-STAT Alinity are handheld POC blood gas/chemistry analyzers widely deployed in U.S. hospitals, EDs, and critical care—the same end markets OPTI serves with its CCA-TS2.
• Nova Biomedical: Manufactures the Stat Profile Prime and pHOx Ultra blood gas/critical care analyzer lines with a maintenance-free sensor approach. Competes with OPTI in hospital POC and critical care settings.
• Siemens Healthineers: Markets the RAPIDPoint 500e blood gas analyzer for POC and the RAPIDLab 1200 series for central lab use. Competes head-to-head with OPTI in hospital blood gas/electrolyte testing.
• Becton Dickinson (BD): BD entered blood gas through the Bard and SNAP-related franchises and offers POC analyzers used in hospital settings. Broadly comparable as a medical device incumbent in critical care diagnostics.
• bioMérieux (BioFire): BioFire FilmArray multiplex PCR panels (including respiratory panels) compete with OPTI's SARS-CoV-2/Flu A/B test in hospital and reference labs. Most direct molecular diagnostics peer on the PCR/menu side.

Broad incumbents

• Roche Diagnostics: Global diagnostics leader with cobas blood gas and broader central-lab chemistry/immunoassay platforms. Indirect competitor via integrated hospital lab solutions and previously the parent of OPTI's lineage (acquired Critical Care Division in 2003).
• QuidelOrtho: Owns the Triage MeterPro POC platform and Sofia rapid immunoassay franchise with hospital lab and ED presence. Comparable as a diversified POC diagnostics incumbent with overlapping menu and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/opti-medical-systems

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Opti Medical Systems